TSFAE23a:	Subjects With Related Treatment-emergent Serious Adverse Events by Preferred Term; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
Preferred Term, n (%) 	N=53 	N=73 	N=126 	N=59 	
Subjects with ≥1 related SAE 	7 (13.2%) 	13 (17.8%) 	20 (15.9%) 	15 (25.4%) 	
 	 	 	 	 	
DIARRHOEA 	1 (1.9%) 	1 (1.4%) 	2 (1.6%) 	0 	
ABDOMINAL DISCOMFORT 	1 (1.9%) 	0 	1 (0.8%) 	0 	
BACK PAIN 	1 (1.9%) 	0 	1 (0.8%) 	0 	
CHEST PAIN 	1 (1.9%) 	0 	1 (0.8%) 	0 	
CHILLS 	1 (1.9%) 	0 	1 (0.8%) 	0 	
CONFUSIONAL STATE 	1 (1.9%) 	0 	1 (0.8%) 	1 (1.7%) 	
CONTUSION 	0 	1 (1.4%) 	1 (0.8%) 	0 	
DIZZINESS 	0 	1 (1.4%) 	1 (0.8%) 	0 	
DYSPHONIA 	0 	1 (1.4%) 	1 (0.8%) 	0 	
DYSURIA 	0 	1 (1.4%) 	1 (0.8%) 	0 	
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED 	0 	1 (1.4%) 	1 (0.8%) 	1 (1.7%) 	
FALL 	0 	1 (1.4%) 	1 (0.8%) 	0 	
FATIGUE 	0 	1 (1.4%) 	1 (0.8%) 	0 	
HEADACHE 	0 	1 (1.4%) 	1 (0.8%) 	0 	
INCREASED APPETITE 	1 (1.9%) 	0 	1 (0.8%) 	0 	
MALAISE 	1 (1.9%) 	0 	1 (0.8%) 	0 	
NAUSEA 	1 (1.9%) 	0 	1 (0.8%) 	0 	
OEDEMA PERIPHERAL 	0 	1 (1.4%) 	1 (0.8%) 	1 (1.7%) 	
PYREXIA 	0 	1 (1.4%) 	1 (0.8%) 	0 	
RHINORRHOEA 	0 	1 (1.4%) 	1 (0.8%) 	0 	
SINUS BRADYCARDIA 	1 (1.9%) 	0 	1 (0.8%) 	0 	
SOMNOLENCE 	0 	1 (1.4%) 	1 (0.8%) 	0 	
TRANSIENT ISCHAEMIC ATTACK 	0 	1 (1.4%) 	1 (0.8%) 	0 	
VENTRICULAR EXTRASYSTOLES 	0 	1 (1.4%) 	1 (0.8%) 	0 	
ABDOMINAL PAIN 	0 	0 	0 	1 (1.7%) 	
AGITATION 	0 	0 	0 	1 (1.7%) 	
BUNDLE BRANCH BLOCK RIGHT 	0 	0 	0 	1 (1.7%) 	
CERVICITIS 	0 	0 	0 	1 (1.7%) 	
CONJUNCTIVITIS 	0 	0 	0 	1 (1.7%) 	
CONSTIPATION 	0 	0 	0 	1 (1.7%) 	
DELUSION 	0 	0 	0 	1 (1.7%) 	
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION 	0 	0 	0 	2 (3.4%) 	
ELECTROCARDIOGRAM T WAVE INVERSION 	0 	0 	0 	1 (1.7%) 	
EYE PRURITUS 	0 	0 	0 	1 (1.7%) 	
HYPERHIDROSIS 	0 	0 	0 	1 (1.7%) 	
HYPOTENSION 	0 	0 	0 	1 (1.7%) 	
MYOCARDIAL INFARCTION 	0 	0 	0 	1 (1.7%) 	
PRURITUS 	0 	0 	0 	1 (1.7%) 	
RASH 	0 	0 	0 	1 (1.7%) 	
SUPRAVENTRICULAR EXTRASYSTOLES 	0 	0 	0 	1 (1.7%) 	
TACHYCARDIA 	0 	0 	0 	1 (1.7%) 	
UPPER RESPIRATORY TRACT INFECTION 	0 	0 	0 	2 (3.4%) 	
VAGINAL MYCOSIS 	0 	0 	0 	1 (1.7%) 	

Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. 	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.